Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · STATUTE-COMPILATIONS · FDA Reauthorization Act of 2017 · Sec. 804

Sec. 804. ACCURATE INFORMATION ABOUT DRUGS WITH LIMITED COMPETITION

740 words·~3 min read·/statute-compilations/comps-15234/sec-804

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

## SEC. 804 ACCURATE INFORMATION ABOUT DRUGS WITH LIMITED COMPETITION Chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended by inserting after section 506H, as added by section 803, the following: > > ## “SEC. 506I PROMPT REPORTS OF MARKETING STATUS > > **[**[21 U.S.C. 356i](/us/usc/t21/s356i)**]** > > > ### “(a) Notification of Withdrawal > > The holder of an application approved under subsection
(c)or
(j)of section 505 shall notify the Secretary in writing 180 days prior to withdrawing the approved drug from sale, or if 180 days is not practicable as soon as practicable but not later than the date of withdrawal. The holder shall include with such notice the— > > > #### “(1) > > National Drug Code; > > > #### “(2) > > identity of the drug by established name and by proprietary name, if any; > > > #### “(3) > > new drug application number or abbreviated application number; > > > #### “(4) > > strength of the drug; > > > #### “(5) > > date on which the drug is expected to no longer be available for sale; and > > > #### “(6) > > reason for withdrawal of the drug. > > > ### “(b) Notification of Drug Not Available for Sale > > The holder of an application approved under subsection
(c)or
(j)shall notify the Secretary in writing within 180 calendar days of the date of approval of the drug if the drug will not be available for sale within 180 calendar days of such date of approval. The holder shall include with such notice the— > > > #### “(1) > > identity of the drug by established name and by proprietary name, if any; > > > #### “(2) > > new drug application number or abbreviated application number; > > > #### “(3) > > strength of the drug; > > > #### “(4) > > date on which the drug will be available for sale, if known; and > > > #### “(5) > > reason for not marketing the drug after approval. > > > ### “(c) Additional One-time Report > > Within 180 days of the date of enactment of this section, all holders of applications approved under subsection
(c)or
(j)of section 505 shall review the information in the list published under subsection 505(j)(7)(A) and shall notify the Secretary in writing that— > > > #### “(1) > > all of the application holder’s drugs in the active section of the list published under subsection 505(j)(7)(A) are available for sale; or > > > #### “(2) > > one or more of the application holder’s drugs in the active section of the list published under subsection 505(j)(7)(A) have been withdrawn from sale or have never been available for sale, and include with such notice the information required pursuant to subsection
(a)or (b), as applicable. > > > ### “(d) Failure to Meet Requirements > > If a holder of an approved application fails to submit the information required under subsection (a), (b), or (c), the Secretary may move the application holder’s drugs from the active section of the list published under subsection 505(j)(7)(A) to the discontinued section of the list, except that the Secretary shall remove from the list in accordance with subsection 505(j)(7)(C) drugs the Secretary determines have been withdrawn from sale for reasons of safety of effectiveness. > > > ### “(e) Updates > > The Secretary shall update the list published under subsection 505(j)(7)(A) based on the information provided under subsections (a), (b), and
(c)by moving drugs that are not available for sale from the active section to the discontinued section of the list, except that drugs the Secretary determines have been withdrawn from sale for reasons of safety or effectiveness shall be removed from the list in accordance with subsection 505(j)(7)(C). The Secretary shall make monthly updates to the list based on the information provided pursuant to subsections
(a)and (b), and shall update the list based on the information provided under subsection
(c)as soon as practicable. > > > ### “(f) Limitation on Use of Notices > > Any notice submitted under this section shall not be made public by the Secretary and shall be used solely for the purpose of the updates described in subsection (e).” > .
Connectionstraces to 2
Citation graph
cites case law
Sec. 804
ACCURATE INFORMATION ABOUT DRUGS WITH LIMITED COMPETITION
Cites 2Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.